https://t.co/M9Q92h7tsY — The Propell Group (@ThePropellGroup) April 21, 2018
https://t.co/gCU7xdwfi4 — The Propell Group (@ThePropellGroup) April 21, 2018
UK small caps hope to help big pharma cut R&D costs via @FT https://t.co/jjMlq9z8ef — The Propell Group (@ThePropellGroup) April 21, 2018
Takeda sweetens offer for rival Shire to £42.8bn via @FT https://t.co/IrvgdndVB0 — The Propell Group (@ThePropellGroup) April 21, 2018
https://t.co/NNnNEl4cOR — The Propell Group (@ThePropellGroup) April 20, 2018
Shire/Allergan: too many wrinkles via @FT https://t.co/4t96S8HNlX — The Propell Group (@ThePropellGroup) April 20, 2018
Pace of drug price growth slows in US via @FT https://t.co/izGm6vnY8k — The Propell Group (@ThePropellGroup) April 20, 2018
P&G to buy Merck’s consumer health business for €3.4bn via @FT https://t.co/vNJV4ESEIj — The Propell Group (@ThePropellGroup) April 19, 2018
Shire rejects £42.4bn takeover from Japan’s Takeda via @FT https://t.co/lBqPkwvuaI — The Propell Group (@ThePropellGroup) April 19, 2018
Finance chiefs warn on Big Tech’s shift to banking https://t.co/fn7PMXly8U — The Propell Group (@ThePropellGroup) April 19, 2018